Subsequent use of breast cancer biomarkers in routine practice and molecular characterization of breast cancer confirmed different prognostic groups of ER+ breast cancers and heterogeneous benefit from cytotoxic chemotherapy [11, 12]. This evidence concerns the gene ESR1 and breast carcinoma.